Physicians' Academy for Cardiovascular Education

Wide distribution of 10-year and lifetime CV risk in patients with diabetes

News - Oct. 1, 2021

Distribution of cardiovascular risk in type 2 diabetes: results of an analysis using data from CAPTURE study

Presented at the EASD 2021 by: Jan Westerink, MD, PhD – Utrecht, The Netherlands

Introduction and methods

It is well known that patients with diabetes have an increased CV risk, but absolute risk differs between patients. Novel glucose-lowering agents with proven CV benefit, SGLT2is and GLP-1RAs, can be used in diabetes patients to lower CV risk. The use of these agents is supported in the most recent EASD and ESC guidelines.

In this study, distribution of 10-year and lifetime CVD risk were estimated using the DIAL model in patients in the CAPTURE study. In addition, treatment patterns, including use of SGLT2i and GLP-1RAs, were assessed based on risk.

The CAPTURE study was a non-interventional, cross-sectional study in which characteristics of almost 10,000 patients with T2DM were collected in 13 countries across 5 continents in 2019. The DIAL model is an externally validated competing risk-adjusted model for lifetime predictions of MACE and non-CV-related mortality in patients with T2DM.

In this study, high CV risk was defined as 10-year CV risk >10% or lifetime risk >50%.

Main results


This study using data of the CAPTURE study showed that 10-year and lifetime CVD risk are widely distributed. Only a minority of patients receives GLP-1RAs and SGLT2is, with no difference in patients with or without a history of CVD.

Dr. Westerink ended his presentation by saying that shared decision making in the clinical setting can be greatly enhanced by discussions with patients on their 10-year and lifetime CV risk and the estimated benefit that can be gained from preventive interventions.

Share this page with your colleagues and friends: